Comprehensive advisory for Spain's pharmaceutical and chemical industry

Spain’s pharmaceutical and chemical industry concentrates 162 active companies with aggregate revenues of €19.9 billion and a gross margin of 17.5%, positioning it as one of the manufacturing sectors with the highest intellectual capital intensity. Holding an 8.8% share of the European Union pharmaceutical market, Spain is the fourth-largest producer by volume and hosts globally relevant R&D centres, particularly in the Catalan cluster and the Madrid and Basque Country industrial corridors. The sector provides direct employment to approximately 66,901 workers registered with Social Security — a figure that understates its true impact when the knock-on effect on suppliers, CROs and contracted research centres is taken into account. Regulatory pressure from the AEMPS, NHS pricing mechanisms, patent expiry cycles and growing competition from biosimilar medicines create an environment where intangible tax planning and intellectual property management determine long-term profitability.

At BMC we advise reference and generic medicine laboratories, clinical biotech and molecular diagnostics companies, active pharmaceutical ingredient (API) manufacturers and speciality chemical groups. Our highest-value service in this sector is the planning and defence of R&D tax deductions under Article 35 LIS, including coordination with certifying bodies for the issuance of binding reasoned reports before the AEAT. We combine this work with Patent Box structuring — a 60% reduction in the taxable base on qualifying royalties — to maximise the fiscal efficiency of intangible assets developed in Spain, in a sector where an 8.8% European market share reflects an intangible-generating capacity that few industries can match.

For international groups, designing and documenting transfer pricing policies is a non-negotiable priority: the AEAT has intensified its compliance programme targeting related-party transactions in sectors with high intangible density, and investigations can reach back four prior tax years. We help laboratories build defensible transfer pricing policies, prepare documentation required under OECD BEPS Action 13 standards and represent them in audit proceedings or advance pricing agreement (APA) negotiations with the Spanish tax authorities.

The chemical industry — CNAE 20 — faces its own specific challenges: environmental compliance under the REACH Regulation, rising energy costs and the transition towards circular chemistry. We round out our service with grant management covering CDTI, the Carlos III Health Institute and Horizon Europe for translational research projects, and with advisory on corporate transactions — acquisitions of preclinical-stage pipelines, joint ventures for molecule co-development — where intangible asset valuation and specialist due diligence are the axis of the entire deal.

Key services for pharmaceutical companies

R&D tax deductions are the most significant fiscal instrument for the pharmaceutical sector. Spanish corporate tax law (article 35 LIS) allows deductions of 25-42% on qualifying R&D expenditure and 12% for technological innovation activities. Pharmaceutical companies can additionally monetise these deductions when they have insufficient corporate tax liability through the cash-back mechanism, receiving up to 80% of the deduction as a direct payment from the AEAT. Obtaining binding motivated reports from CDTI is essential to protect the deduction in inspections.

Patent Box planning (article 23 LIS) allows a 60% reduction in the taxable base on income from qualifying intangible assets — patents, know-how, trade secrets — provided the nexus approach linking the tax benefit to genuine R&D activity is satisfied. We advise pharmaceutical companies on the design of IP ownership structures that maximise the available Patent Box benefit while satisfying the evolving OECD and EU standards.

Due diligence in pharmaceutical M&A requires scrutiny of regulatory dossiers with the AEMPS and EMA, product liability exposure, reimbursement and pricing agreements with the Spanish National Health System (SNS), supply and distribution contracts, IP portfolio and freedom-to-operate analysis. We coordinate multi-disciplinary teams to deliver comprehensive pharmaceutical due diligence within transaction timescales, integrating tax, legal and financial workstreams.

Regulatory challenges for pharmaceutical companies in Spain

The Spanish pharmaceutical market is one of the most regulated in the EU. The Sistema de Precios de Referencia (reference pricing system), the compulsory rebates for hospital medicines, the prescription medicines information system (SISPARES) and the AEMPS regulatory framework create a complex environment for commercial operations. The management of pricing and reimbursement negotiations with the Ministerio de Sanidad and regional health authorities requires specialist regulatory and legal advisory.

International tax planning for pharmaceutical groups must address the interaction between the Patent Box regime, transfer pricing rules for IP-rich structures and the OECD Pillar Two global minimum tax. Spain’s ETVE regime and participation exemption are particularly relevant for pharmaceutical holding structures with subsidiaries in Latin America, Europe and the US. We advise on the full range of international tax planning instruments available to pharmaceutical groups headquartered or operating in Spain.

KPIs and trends for the Spanish pharmaceutical sector 2025-2026

Spain’s pharmaceutical market generated revenues of more than €26 billion in 2024, with innovative medicines and biologics growing at 8% and generics and biosimilars at 6% year-on-year. The Spanish biotech and pharma R&D sector attracted more than €1.2 billion in venture capital and private equity investment in 2024, positioning Spain as one of Europe’s leading destinations for life sciences investment. The sector employs more than 42,000 researchers and generates exports of €14 billion, making it one of Spain’s most internationally competitive industries.